{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:09:38Z","timestamp":1792206578369,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The use of Attention-Deficit\/Hyperactivity Disorder (ADHD) medications during pregnancy is increasing, raising concerns about potential long-term effects on offspring. This study investigates in utero exposure to methylphenidate, amphetamines and atomoxetine and risk of offspring neurodevelopmental disorders (NDDs). The population-based cohort study identified from Swedish registers included 861,650 children born by 572,731 mothers from 2008\u20132017. We categorized exposure based on redeemed medication during pregnancy and compared exposed children to those whose mothers discontinued medication before conception. Main outcomes were any NDD, including ADHD and autism spectrum disorder (ASD). Cox proportional hazards regression estimated hazard ratios (HRs), adjusting for maternal psychiatric and sociodemographic factors. Sensitivity analyses included stratifications by medication type, timing, and duration of exposure, and sibling comparisons. We also performed a meta-analysis combining data from the present study with those from a previous Danish study. Results showed no increased risk for any NDD (HR<jats:sub>adjusted<\/jats:sub> 0.95, 95% CI 0.82\u20131.11), ADHD (HR<jats:sub>adjusted<\/jats:sub> 0.92, 95% CI 0.78\u20131.08), or ASD (HR<jats:sub>adjusted<\/jats:sub> 0.86, 95% CI 0.63\u20131.18). Sensitivity analyses showed consistent patterns of no increased risks across different exposure durations, medication types and between siblings. Meta-analyses further supported the findings (pooled HR for any NDD 1.00, 95% CI 0.83;1.20). Our study provides evidence that in utero exposure to ADHD medications does not increase the risk of long-term NDDs in offspring. This study replicates safety data for methylphenidate and extends it with new safety data on amphetamines and atomoxetine. These findings are crucial for informing clinical guidelines and helping healthcare providers and expectant mothers make informed decisions.<\/jats:p>","DOI":"10.1038\/s41380-025-02968-4","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:10:07Z","timestamp":1743135007000},"page":"3885-3894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders \u2013 a population-based cohort study and meta-analysis"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-5534","authenticated-orcid":false,"given":"Kathrine","family":"Bang Madsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Skoglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Munk-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Bergink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-9337","authenticated-orcid":false,"given":"Jeffrey H.","family":"Newcorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8075","authenticated-orcid":false,"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3037-5287","authenticated-orcid":false,"given":"Paul","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-2067","authenticated-orcid":false,"given":"Ralf","family":"Kuja-Halkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hove Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Klungs\u00f8yr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Brikell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-2330","authenticated-orcid":false,"given":"Miguel","family":"Garcia-Argibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"2968_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-024-00495-0","volume":"10","author":"SV Faraone","year":"2024","unstructured":"Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. Attention-deficit\/hyperactivity disorder. Nat Rev Dis Primers. 2024;10:11.","journal-title":"Nat Rev Dis Primers"},{"key":"2968_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.15585\/mmwr.mm6702a3","volume":"67","author":"KN Anderson","year":"2018","unstructured":"Anderson KN, Ailes EC, Danielson M, Lind JN, Farr SL, Broussard CS, et al. Attention-deficit\/Hyperactivity disorder medication prescription claims among privately insured women aged 15\u201344 years - United States, 2003\u20132015. MMWR Morb Mortal Wkly Rep. 2018;67:66\u201370.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2968_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/pds.3742","volume":"24","author":"C Louik","year":"2015","unstructured":"Louik C, Kerr S, Kelley KE, Mitchell AA. Increasing use of ADHD medications in pregnancy. Pharmacoepidemiol Drug Saf. 2015;24:218\u201320.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2968_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00228-022-03428-6","volume":"79","author":"JM Cohen","year":"2023","unstructured":"Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad \u00d8. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010\u20132019. Eur J Clin Pharmacol. 2023;79:173\u201380.","journal-title":"Eur J Clin Pharmacol"},{"key":"2968_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40263-024-01076-1","volume":"38","author":"K Bang Madsen","year":"2024","unstructured":"Bang Madsen K, Bliddal M, Skoglund CB, Larsson H, Munk-Olsen T, Madsen MG, et al. Attention-deficit hyperactivity disorder (ADHD) medication use trajectories among women in the perinatal period. CNS Drugs. 2024;38:303\u201314.","journal-title":"CNS Drugs"},{"key":"2968_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40263-020-00728-2","volume":"34","author":"L Li","year":"2020","unstructured":"Li L, Sujan AC, Butwicka A, Chang Z, Cortese S, Quinn P, et al. Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS Drugs. 2020;34:731\u201347.","journal-title":"CNS Drugs"},{"key":"2968_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/pds.3600","volume":"23","author":"KB Haervig","year":"2014","unstructured":"Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23:526\u201333.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2968_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.genhosppsych.2021.09.003","volume":"73","author":"EA Damer","year":"2021","unstructured":"Damer EA, Edens MA, van der Loos MLM, van Esenkbrink J, Bunkers I, van Roon EN, et al. Fifteen years\u2019 experience with methylphenidate for attention-deficit disorder during pregnancy: effects on birth weight, apgar score and congenital malformation rates. Gen Hosp Psychiatry. 2021;73:9\u201315.","journal-title":"Gen Hosp Psychiatry"},{"key":"2968_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.2019.20008","volume":"323","author":"P Damkier","year":"2020","unstructured":"Damkier P, Broe A. First-trimester pregnancy exposure to modafinil and risk of congenital malformations. JAMA. 2020;323:374\u20136.","journal-title":"JAMA"},{"key":"2968_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2017.3644","volume":"75","author":"KF Huybrechts","year":"2018","unstructured":"Huybrechts KF, Br\u00f6ms G, Christensen LB, Einarsd\u00f3ttir K, Engeland A, Furu K, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry. 2018;75:167\u201375.","journal-title":"JAMA Psychiatry"},{"key":"2968_CR11","doi-asserted-by":"publisher","first-page":"e20170747","DOI":"10.1542\/peds.2017-0747","volume":"140","author":"U N\u00f6rby","year":"2017","unstructured":"N\u00f6rby U, Winbladh B, K\u00e4ll\u00e9n K. Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatrics. 2017;140:e20170747.","journal-title":"Pediatrics"},{"key":"2968_CR12","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.4088\/JCP.15m10083","volume":"77","author":"O Diav-Citrin","year":"2016","unstructured":"Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E, et al. Methylphenidate in pregnancy: a multicenter, prospective, comparative, observational study. J Clin Psychiatry. 2016;77:1176\u201381.","journal-title":"J Clin Psychiatry"},{"key":"2968_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/CLEP.S72906","volume":"7","author":"SP Bro","year":"2015","unstructured":"Bro SP, Kjaersgaard MI, Parner ET, S\u00f8rensen MJ, Olsen J, Bech BH, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139\u201347.","journal-title":"Clin Epidemiol"},{"key":"2968_CR14","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.4088\/JCP.13m08708","volume":"75","author":"A Potteg\u00e5rd","year":"2014","unstructured":"Potteg\u00e5rd A, Hallas J, Andersen JT, L\u00f8kkegaard EC, Dideriksen D, Aagaard L, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:e88\u201393.","journal-title":"J Clin Psychiatry"},{"key":"2968_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/1087054718759753","volume":"24","author":"KN Anderson","year":"2020","unstructured":"Anderson KN, Dutton AC, Broussard CS, Farr SL, Lind JN, Visser SN, et al. ADHD Medication use during pregnancy and risk for selected birth defects: National Birth Defects Prevention Study, 1998\u20132011. J Atten Disord. 2020;24:479\u201389.","journal-title":"J Atten Disord"},{"key":"2968_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40263-018-0505-9","volume":"32","author":"AS Poulton","year":"2018","unstructured":"Poulton AS, Armstrong B, Nanan RK. Perinatal outcomes of women diagnosed with attention-deficit\/hyperactivity disorder: An Australian Population-Based Cohort Study. CNS Drugs. 2018;32:377\u201386.","journal-title":"CNS Drugs"},{"key":"2968_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/AOG.0000000000002362","volume":"130","author":"JM Cohen","year":"2017","unstructured":"Cohen JM, Hern\u00e1ndez-D\u00edaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol. 2017;130:1192\u2013201.","journal-title":"Obstet Gynecol"},{"key":"2968_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/pds.4716","volume":"28","author":"H-Y Jiang","year":"2019","unstructured":"Jiang H-Y, Zhang X, Jiang C-M, Fu H-B. Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2019;28:288\u201395.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2968_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41380-023-01992-6","volume":"28","author":"K Bang Madsen","year":"2023","unstructured":"Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW, et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023;28:1739\u201346.","journal-title":"Mol Psychiatry"},{"key":"2968_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/jamapsychiatry.2023.5073","volume":"81","author":"EA Suarez","year":"2024","unstructured":"Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, et al. Prescription stimulant use during pregnancy and risk of neurodevelopmental disorders in children. JAMA Psychiatry. 2024;81:477\u201388.","journal-title":"JAMA Psychiatry"},{"key":"2968_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/0269881117699361","volume":"31","author":"RH McAllister-Williams","year":"2017","unstructured":"McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, et al. British association for psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31:519\u201352.","journal-title":"J Psychopharmacol"},{"key":"2968_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biopsych.2019.04.009","volume":"86","author":"Z Chang","year":"2019","unstructured":"Chang Z, Ghirardi L, Quinn PD, Asherson P, D\u2019Onofrio BM, Larsson H. Risks and benefits of attention-deficit\/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry. 2019;86:335\u201343.","journal-title":"Biol Psychiatry"},{"key":"2968_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00737-024-01450-4","volume":"27","author":"DJ Russell","year":"2024","unstructured":"Russell DJ, Wyrwoll CS, Preen DB, Kelty E. Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study. Arch Womens Ment Health. 2024;27:785\u201394.","journal-title":"Arch Womens Ment Health"},{"key":"2968_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AE, Ljung R, Michaelsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125\u201336.","journal-title":"Eur J Epidemiol"},{"key":"2968_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10654-022-00947-5","volume":"38","author":"S Cnattingius","year":"2023","unstructured":"Cnattingius S, K\u00e4ll\u00e9n K, Sandstr\u00f6m A, Rydberg H, M\u00e5nsson H, Stephansson O, et al. The Swedish medical birth register during five decades: documentation of the content and quality of the register. Eur J Epidemiol. 2023;38:109\u201320.","journal-title":"Eur J Epidemiol"},{"key":"2968_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"key":"2968_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2968_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Svedberg P, Ol\u00e9n O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34:423\u201337.","journal-title":"Eur J Epidemiol"},{"key":"2968_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"2968_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.euroneuro.2021.01.003","volume":"44","author":"M Lemelin","year":"2021","unstructured":"Lemelin M, Sheehy O, Zhao JP, B\u00e9rard A. Maternal ADHD medication use during pregnancy and the risk of ADHD in children: importance of genetic predispositions and impact of using a sibling analysis. Eur Neuropsychopharmacol. 2021;44:66\u201378.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2968_CR31","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00787-022-02034-2","volume":"32","author":"AMS S\u00f8rensen","year":"2023","unstructured":"S\u00f8rensen AMS, Wesselh\u00f6eft R, Andersen JH, Reutfors J, Cesta CE, Furu K, et al. Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010\u20132020. Eur Child Adolesc Psychiatry. 2023;32:2049\u201356.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2968_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00787-019-01416-3","volume":"29","author":"E Barrett","year":"2020","unstructured":"Barrett E, Jacobs B, Klasen H, Herguner S, Agnafors S, Banjac V, et al. The child and adolescent psychiatry: study of training in Europe (CAP-STATE). Eur Child Adolesc Psychiatry. 2020;29:11\u201327.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2968_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/pds.5490","volume":"31","author":"L Rasmussen","year":"2022","unstructured":"Rasmussen L, Wettermark B, Steinke D, Potteg\u00e5rd A. Core concepts in pharmacoepidemiology: measures of drug utilization based on individual-level drug dispensing data. Pharmacoepidemiol Drug Saf. 2022;31:1015\u201326.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02968-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02968-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02968-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:28:39Z","timestamp":1757147319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02968-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2968"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-02968-4","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KBM has received speakers fee from MEDICE within the last 3 years. HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire\/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit\/hyperactivity disorder from Shire\/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. HL is editor-in-chief of JCPP Advances. CS is founder and owner of a private Swedish clinic for assessment and treatment of ADHD in children and adults (SMART Psykiatri) and the founder of a digital selfcare tool for female ADHD (Letterlife). CS has participated at advisory boards, served as invited speaker and received honorariums\/travel expenses from Shire\/Takeda, Nordic Drugs, UCB Pharma, DNE Pharma, Novartis, Evolan, Lundbeck A\/S, Gideon Richter and Medice during 2017\u20132024, serve as PI for research supported by Takeda 2022\u20132024 and receive royalties for popular science books on ADHD from publishing houses in Sweden, Denmark, Estonia, UK, USA, Canada, Australia, New Zeeland, Poland, Germany, France, Korea and China. SC has declared reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH) in relation to lectures delivered for ACAMH, the Canadian AADHD Alliance Resource, the British Association of Psychopharmacology, and from Healthcare Convention for educational activity on ADHD, and has received honoraria from Medice. JN reports the following disclosures (all unrelated to this work): consultant\/advisory board for Adlon Therapeutics, Arbor, Corium, Lumos, Medice, Myriad, NLS, OnDosis, Rhodes, and Supernus; research support from Adlon, Otsuka, Shire, Supernus; honoraria for disease state lectures from Otsuka and Takeda and served as a consultant for the US National Football League. PHT has received speakers fee from MEDICE and Takeda within last 3 years. TMO has received speakers fee from Lundbeck A\/S within the last 3 years. All other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}